Company intelligence / Profile preview

Summit Biosciences

Lexington, Kentucky, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~72
Development stage: Commercial

Overview

Summit Biosciences specialized in the development, manufacturing, and commercialization of prescription nasal spray products. The company had an extensive track record of innovation in unit dose nasal spray medicines with FDA/EMA-approved facilities. In January 2024, it was acquired by Kindeva Drug Delivery to expand their capabilities in intranasal drug-device combination products. Clinical results for specific programs are not publicly detailed.

Therapeutic areas: Neurology
Modalities: Nasal spraysIntranasal drug delivery
Industry: Contract Manufacturing Organization

Drug pipeline

4 assets

NARCAN

Commercial

Indications: Opioid overdose

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Summit Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Summit Biosciences.

Explore the full profile